Sector News

Bigger pharma may be scraping for good deals, but Horizon has plenty of options, analysts say

June 29, 2015
Life sciences
Horizon Pharma isn’t exactly the only specialty pharma company hunting for deals. Allergan, Mallinckrodt, Endo and the ever-acquisitive Valeant have all been on shopping sprees lately, leaving some analysts wondering just what’s left worth buying in the space. But Horizon is much smaller than its specialty peers–meaning it’s got plenty of opportunities, UBS analysts figure.
 
In a research report seen by Investor’s Business Daily, UBS’ Marc Goodman and Ami Fadia pointed out that Horizon–with a market cap just over $5 billion–is at least $9 billion smaller than other on-the-prowl specialty pharmas, meaning it’s “playing in a different sandbox.”
 
Because of its track record and balance sheet, Horizon “has hit the radar of more potential sellers of assets,” leading the analysts to up both their price target on the company’s stock and their revenue estimates.
 
That’s music to the ears of CEO Timothy Walbert, who has said he’s building up Horizon’s leadership and infrastructure “to support a larger organization,” the UBS analysts wrote. Recently, that’s involved foraying into the orphan-drug business with a pickup of osteoporosis treatment Actimmune–and following that up with May’s $1.1 billion acquisition of orphan drugmaker Hyperion.
 
And while it may have once looked like Horizon would need new offerings to fill in for Vimovo and Duexis–a pair of flagship products Express Scripts and CVS booted off their preferred formulary lists last year–sales of those drugs have held up, IBD notes, meaning pickups can only boost things further. The analysts credit that to the company’s “prescriptions made easy” sales method, one they say is “really the key differentiating piece for Horizon.”
 
By Carly Helfand
 

comments closed

Related News

September 25, 2022

Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences

Life sciences

Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.

September 25, 2022

Mount Sinai AI uncovers new brain analysis method to predict dementia, Alzheimer’s disease

Life sciences

Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.

September 25, 2022

New AstraZeneca-backed report finds big money behind diverse owners and entrepreneurs in Europe

Life sciences

There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.